What You Should Know:
- A new survey shows that remote clinical trials are not just a convenient option but a key factor in whether people choose to participate in research at all.
- The survey, conducted by digital healthcare solutions provider Vivalink, found that nearly 90% of Americans are open to participating in fully remote trials, signaling a major shift in patient expectations.
A Clear Preference for Virtual Trials
The survey, which polled over 200 U.S. adults,
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
M&A: Evident to Acquire Digital Pathology Solution Pramana
What You Should Know:
- Evident, a leader in clinical microscopy and superior optics, today announced a definitive agreement to acquire Pramana, Inc., a manufacturer of digital pathology solutions. Financial details of the acquisition were not disclosed.
- The strategic acquisition brings together Pramana’s cutting-edge autonomous whole slide imaging technologies with Evident’s longstanding expertise to revolutionize the market for digital pathology solutions and usher in what both
Read More
Why MedTech Needs Regulatory Intelligence, Not Just Regulatory Updates
In the past five years, medical device companies have faced continuous change, with new regulations, evolving standards, and increasing documentation requirements. The 2024 MTI Regulatory Report put it plainly: “time and bandwidth” have now overtaken cost as the biggest challenge for regulatory affairs teams.
This shift points to a deeper issue. The volume and pace of regulatory change have outgrown traditional compliance approaches. Tracking updates and reacting as they come is no longer
Read More
How Sensor Technology Is Transforming Clinical Trials
Clinical trials are the foundation of drug development, generating life-saving medicines for the betterment of society. But trials can be arduous, lengthy, and expensive for patients, sites, and sponsors, particularly in neurological disease trials, where phase III trials cost up to $370 million, last 7.9 years, and face a 95% failure rate among drug candidates 1,2,3. Moreover, traditional site-based data collection methods do not capture the complete picture of how patients are affected by
Read More
Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline
What You Should Know:
- After a strong start to the year, the digital health sector experienced a significant pullback in Q2 2025, with deal volume declining to its lowest quarterly activity level in the last five years, according to the latest report from Silicon Valley Bank (SVB).
- The report, Mid-Year Healthcare Investment and Exits Report reveals growing investor selectivity and capital concentration in fewer, high-conviction bets amidst ongoing global economic
Read More
Briya Launches AIRE™: The World’s First Clinical-Grade AI Research Assistant to Accelerate Biomedical Discovery
What You Should Know:
- Briya, a health technology company redefining medical research launches Briya AIRE™, the world's first clinical-grade AI research assistant built to accelerate biomedical and clinical decision-making.
- Designed to "think" in the language of medicine, clinical research, and epidemiology, AIRE aims to transform months of manual data analysis into actionable insights in minutes, enabling faster, cost-effective discovery across biopharma and academic research
Read More
Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years
What You Should Know:
- Advancements in accelerating early Alzheimer’s disease (AD) screening and access to care, proven from three diverse community pilot initiatives, were presented today during a podium presentation at the Alzheimer’s Association International Conference® 2025 (AAIC). The study, entitled “Remote Collection of Biomarkers for Alzheimer’s Disease and Related Disorders,” validated Neurogen’s new ecosystem, which brings together the first in-home blood biomarker testing
Read More
Flatiron Health Triples Global Oncology Research Network
What You Should Know:
- Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced that its international oncology research network has tripled in size across the UK, Germany, and Japan over the past year—a milestone that marks an unprecedented acceleration in global cancer research collaboration and impact.
- Flatiron Health entered international markets to address the growing unmet need for
Read More
Sanofi Acquires Vicebio for $1.15B, Bolstering Vaccine Pipeline
What You Should Know:
- Sanofi has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition expands Sanofi’s capabilities in vaccine design and development with Vicebio’s innovative ‘Molecular Clamp’ technology and brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) into its pipeline.
- The vaccine candidate complements
Read More
Unlocking the Power of Genomics in Clinical Trials: A Precision Medicine Data Imperative
As precision medicine continues to reshape the future of healthcare, clinical trials are evolving from one-size-fits-all studies into highly targeted investigations driven by genomics and biomarker-based insights. These trials not only test therapeutic efficacy but also help identify which patients are most likely to benefit, reducing trial-and-error in treatment and transforming hope into more predictable outcomes. With nearly half a million clinical trials underway globally, the potential to
Read More
